Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG0905 osteosarcoma MAP vs MAP + ifosfamide study
jRCTs031180126Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate, doxorubicin, cisplatin and ifosfamide in osteosarcoma (OS) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Disease-free survival. Started Apr 2010; status: active, not recruiting.
02
Drugs
methotrexatedoxorubicincisplatinifosfamide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on jRCTs031180126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180126.